http://hdl.handle.net/123456789/2125 Search the Channel search http://repository.ksu.edu.sa/jspui/simple-search http://hdl.handle.net/123456789/4979 Title: Beibersteneolide-a and -b: two new sesquiterpene lactones from achillea beiberstenii<br/><br/>Authors: Al-Howiriny, Tawfeq A; Mossa, Jaber S; Ahmed, Bahar<br/><br/>Abstract: The aerial part of Achillea beiberstenii (Composite) has afforded two new sesquiterpene lactones, ciiaracitnzta as 3a,9fi-diacctoxy-l[3,IO-cpoxy-5(4)-cn-gcrmacran-6p,12-olide, named as beibcrstcncolide-a 1, and 4.9p-dihydroxy-2(0,6(5),I l(l3)-triene-guaian-7a,12-oiide, designated as beiberstcneolide-b 2. The structures of the isolated compounds have been elucidated on the basis of spectral studies.<br/><br/>Description: 3 Medicinal, Aromaiic and Poisonous Plants Research Center Department of Pharmacognosy, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia; Department of Pharmacognosy, College of Pharmacy, King Saud University Sat, 01 Jan 2005 00:00:00 GMT http://hdl.handle.net/123456789/4884 Title: Testosterone solid lipid microparticles for transdermal drug delivery:formulation and physicochemical characterization<br/><br/>Authors: El-Kamel, Amal H.; Al-Fagih, Iman M.; Alsara, Ibrahim A.<br/><br/>Abstract: Purpose: The main objective of the study was to formulate and characterize testosterone (TS) solid lipid microparticles (SLM) to be applied as a transdermal delivery system. Methods: Testosterone SLMs were formulated using an emulsion melt homogenization method. Various types and concentrations of fatty materials, namely glyceryl monostearate (GM), glyceryl distearate (GD), stearic acid (SA) and glyceryl behanate (GB) were used. The formulations contained 2.5 or 5 mg TS g-1. Morphology, particle size, entrapment efficiency (EE), rheological properties and thermal behaviour of the prepared SLM were examined. In vitro release characteristics of TS from various prepared SLM were also evaluated over 24 h using a vertical Franz diffusion cell. In addition, the effect of storage and freeze-drying on particle size and release pattern of TS from the selected formulation was evaluated. Results: The results indicated that the type of lipid affected the morphology and particle size of SLM. A relatively high drug percentage entrapment efficiency ranging from 80.7-95.7% was obtained. Rheological studies showed plastic flow characteristics of the prepared formulations. DSC examination revealed that TS existed in amorphous form in the prepared SLM. Release studies revealed the following rank order of TS permeation through cellophane membrane after application of various formulations: 5% GM<5% GD<5% SA<5% GB<2.5% GM<2.5% SA<10% GD<10% GB. The drug permeation through excised abdomen rat skin after application of 10% GB-2.5 mg TS g-1 SLM was lower than that permeated through cellophane membrane. Moreover, SLM containing 10% GB-2.5 mg TS g-1 stored at 5°C showed good stability as indicated by the release study and particle size analysis. Trehalose showed high potential as a cryoprotectant during freeze drying of the selected SLM formulation. Conclusions: The developed TS SLM delivery system seemed to be promising as a TS transdermal delivery system.<br/><br/>Description: Faculty of Pharmacy, Department of Pharmaceutics, King Saud University, Riyadh, Saudi Arabia Wed, 01 Aug 2007 00:00:00 GMT http://hdl.handle.net/123456789/3239 Title: Micromatricial metronidazole benzoate film as a local mucoadhesive delivery system for treatment of periodontal diseases<br/><br/>Authors: El-Kamel, Amal Hassan; Ashri, Lubna Y.; Alsarra, Ibrahim A.<br/><br/>Abstract: The main objective of this study was to develop a local,oral mucoadhesive metronidazole benzoate (MET) deliverysystem that can be applied and removed by the patient forthe treatment of periodontal diseases. Mucoadhesive micromatricialchitosan/poly(ε-caprolactone) (CH/PCL) filmsand chitosan films were prepared. Thermal behavior,morphology, and particle size measurements were used toevaluate the prepared films. The effect of different molarmasses of CH and different ratios of medium Mwt molarmass chitosan (MCH):PCL on water absorption, in vitrobioadhesion, mechanical properties, and in vitro drugrelease was examined. In vivo performance of the selectedformulation was also evaluated. Differential scanningcalorimetry examination revealed that MET existed mainlyin amorphous form. Under microscopic examination, PCLmicroparticles were homogeneously dispersed in the films.The use of different molar masses of CH and differentratios of (MCH):PCL affected the size of the entrappedparticles. Addition of PCL significantly decreased percentagewater uptake and bioadhesion force compared withpure CH film. With regard to mechanical properties, the 2-layered film containing 1:0.625 MCH:PCL had the besttensile properties. At fixed CH:PCL ratio (1:1.25), theslowest drug release was obtained from films containinghigh molar mass CH. On the other hand, the 2-layered filmthat consisted of 1:0.625 MCH:PCL had the slowest METrelease. In vivo evaluation of the selected film revealed thatmetronidazole concentration in saliva over 6 hours rangedfrom 5 to 15 μg/mL, which was within and higher than thereported range of minimum inhibitory concentration formetronidazole. A significant in vitro/in vivo correlationunder the adopted experimental conditions was obtained. Mon, 01 Jan 2007 00:00:00 GMT http://hdl.handle.net/123456789/2977 Title: Bioequivalence evaluation of norfloxacin 400 mg tablets (uroxin and noroxin) in healthy human volunteers<br/><br/>Authors: Al-Rashood, Khalid A.; Al-Khamis, Khalil I.; El-Sayed, Yoursy M.; Al-Bella, Sulaiman; Al-Yamani, Mohd A.; Alam, S. Mahmood; Dham, Ruwayda<br/><br/>Abstract: A bioequivalence study of two oral formulations of 400 mg norfloxacin was carried out in 18 healthy volunteers according to a single dose, two-sequence, cross-over randomized design at College of Pharmacy, King Saud University, Riyadh, Saudi Arabia, jointly with King Khalid University Hospital. The two formulations were: Uroxin® (Julphar, United Arab Emirates) as test and Noroxin® (Merck Sharpe & Dohme, BV, Netherlands). Both test and reference formulations were administered to each subject after an overnight fasting on 2 treatment days separated by 1 week wash-out period. After dosing, serial blood samples were collected for a period of 24 h. Plasma harvested from blood, was analysed for norfloxacin by a sensitive, reproducible and accurate HPLC method. Various pharmacokinetic parameters including AUC0–t, AUC0– , Cmax, Tmax, T1:2, and Kel were determined from plasma concentrations for both the formulations and found to be in good agreement with reported values. AUC0–t, AUC0– , and Cmax were tested for bioequivalence after log-transformation of data. No significant difference was found based on ANOVA; 90% confidence interval for test:reference ratio of these parameters were found within a bioequivalence acceptance range of 80–125%. Based on these statistical inferences, it was concluded that Uroxin is bioequivalent to Noroxin.Sons, Ltd. Sat, 01 Jan 2000 00:00:00 GMT